Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Blood (2019) 134 (Supplement_1): 4296.

https://doi.org/10.1182/blood-2019-128470

Published: 2019

Journal Articles

Design of a NGS Platform for the Integrated Analysis of Genetic Mutations, Copy Number Alteration and Somatic Hypermutation of IGHV in CLL

Miguel Alcoceba, PhD, Maria Garcia-Alvarez, B.Sc., Anna Puiggros, PhD, Luis Espinosa-Hevia, PhD, Andrea Gómez-Llonín, B.Sc., Almudena Navarro, MD, Jose Maria Bastida, MD PhD, Norma C. Gutierrez, MD PhD, Jose A. Garcia-Marco, MD PhD, Blanca Espinet, PhD, Ramón García-Sanz, MD PhD, Marcos González, MD PhD

Blood (2018) 132 (Supplement 1): 1851.

https://doi.org/10.1182/blood-2018-99-114995

Published: 2018

Journal Articles

Complement Genotype and Multiparametric Laboratory Analysis to Predict Response to Eculizumab and to Adjust Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

Marta Subías-Hidalgo, PhD, Alicia Lopez, PhD, Jaouad Anter, PhD, Sheila Pinto, PhD, Emilio Ojeda, MD, Jose A Garcia-Marco, MD PhD, Fernando Ataulfo Gonzalez-Fernandez, MD, Rafael Fores, MD, Laura Llorente, MD, Ana Maria Villegas-Martinez, MD, Santiago Rodriguez-Cordoba, MD

Blood (2015) 126 (23): 2139.

https://doi.org/10.1182/blood.V126.23.2139.2139

Published: 2015

Journal Articles

High Cardiac Output By Microfistulas: A New Pulmonary Hypertension Mechanism in Patients with Myelofibrosis and the Impact of the Treatment with Ruxolitinib

Jose Maria Segovia, MD, Emilio Ojeda, MD, Gomez-Bueno Manuel Francisco, MD, Rafael Fores, MD, Jose A Garcia-Marco, MD PhD, Francisco Javier Haro, MD, Isabel Salcedo, PhD, Carlos DeMiguel, MD

Blood (2015) 126 (23): 4065.

https://doi.org/10.1182/blood.V126.23.4065.4065

Published: 2015

Journal Articles

Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results

Tadeusz Robak, MD, Andrzej Hellman, Javier Loscertales, MD, Ewa Lech-Maranda, MD PhD, John M. Pagel, MD PhD, Anthony R. Mato, MD, John C. Byrd, MD, Farrukh Awan, MD MS, Holger Hebart, MD, Jose A Garcia-Marco, MD PhD, Brian T. Hill, MD PhD, Michael Hallek, MD, Scott Stromatt, Janusz Kloczko, Professor

Blood (2014) 124 (21): 5642.

https://doi.org/10.1182/blood.V124.21.5642.5642

Published: 2014

Journal Articles

Paroxysmal Nocturnal Hemoglobinuria and Thrombosis Before and After Eculizumab

Cristina Muñoz-Linares, MD, Miguel Pastrana, MD, Emilio Ojeda, MD, PhD, Rafael Fores, MD, Martin Cabero, MD, Daniel Morillo, MD, Guiomar Bautista, MD, Belen Navarro, MD, Isabel Krsnik, MD, PhD, Santiago Gil, MD, PhD, Carmen Regidor, MD, PhD, Almudena de LaIglesia, MD, Jose Luis Bueno, MD, Jose A Garcia-Marco, MD, PhD, Jose Rafael Cabrera, MD, PhD

Blood (2013) 122 (21): 1242.

https://doi.org/10.1182/blood.V122.21.1242.1242

Published: 2013

Journal Articles

Paroxysmal Nocturnal Hemoglobinuria and Cancer: High Incidence Of Cancer In a Large Series Of PNH Patients In a Single Center

Cristina Muñoz-Linares, MD, Emilio Ojeda, MD, PhD, Rafael Fores, MD, Martin Cabero, MD, Daniel Morillo, MD, Guiomar Bautista, MD, Belen Navarro, MD, Isabel Krsnik, MD, PhD, Santiago Gil, MD, PhD, Almudena de LaIglesia, MD, Carmen Regidor, MD, PhD, Jose Luis Bueno, MD, Jose A Garcia-Marco, MD, PhD, Jose Rafael Cabrera, MD, PhD

Blood (2013) 122 (21): 4871.

https://doi.org/10.1182/blood.V122.21.4871.4871

Published: 2013

Journal Articles

Paroxysmal Nocturnal Hemoglobinuria and Magnetic Resonance Imaging

Miguel Pastrana, MD, Cristina Muñoz-Linares, MD, Emilio Ojeda, MD, PhD, Rafael Fores, MD, Beatriz Brea, MD, Martin Cabero, MD, Daniel Morillo, MD, Guiomar Bautista, MD, Belen Navarro, MD, Isabel Krsnik, MD, PhD, Almudena de LaIglesia, MD, Santiago Gil, MD, PhD, Carmen Regidor, MD, PhD, Jose Luis Bueno, MD, Jose A Garcia-Marco, MD, PhD, Jose Rafael Cabrera, MD, PhD

Blood (2013) 122 (21): 4873.

https://doi.org/10.1182/blood.V122.21.4873.4873

Published: 2013

Journal Articles

Efficacy and Safety Of Temsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma: Results From The Spanish Experience

Blood (2013) 122 (21): 5117.

https://doi.org/10.1182/blood.V122.21.5117.5117

Published: 2013

Journal Articles

Use of Romiplostim to Facilitate Platelet Engraftment in Allogeneic Hematopoietic Transplantation

Emilio Ojeda, MD, PhD, Jose A. Garcia-Marco, MD, PhD, Belen Navarro, MD, Almudena DelaIglesia, MD, Rafael Fores, MD, Guiomar Bautista, MD, Isabel Krsnik, MD, PhD, Amelia Sanchez-Guerrero, PhD, Isabel SanJuan, MD, Carmen Regidor, MD, Santiago Gil, MD, PhD, Rosa Gonzalo-Daganzo, Biol, PhD, Trinidad Martin-Donaire, MD, Ph, Rocio Sanchez, ND, Gracia Bravo, ND, Nuria Claros, MD, Martin Cabero, MD, Pilar Beltran, MD, Jose Rafael Cabrera, MD, PhD

Blood (2011) 118 (21): 1947.

https://doi.org/10.1182/blood.V118.21.1947.1947

Published: 2011

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Francesc Bosch, MD, PhD, Pau Abrisqueta, Neus Villamor, MD. PhD, María José Terol, MD, PhD, Eva González-Barca, MD, Marcos González, MD, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD

Blood (2011) 118 (21): 293.

https://doi.org/10.1182/blood.V118.21.293.293

Published: 2011

Journal Articles

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Blood (2010) 116 (21): 2448.

https://doi.org/10.1182/blood.V116.21.2448.2448

Published: 2010

Journal Articles

Pharmacological Inhibition of PIM Kinases In Chronic Lymphocytic Leukemia Cases with Unfavorable Prognosis Markers

Beatriz Herreros, James R. Bischoff, Maria E. Rodriguez, Margarita Sanchez-Beato, Elena Domenech, Carmen Blanco, Cristina I. Gomez-Abad, Raul Cordoba, Julio Delgado, Jose A Garcia-Marco, MD, PhD, Juan F. Garcia, José Francisco Tomás, Joaquín Martínez-López, Antonia Rodriguez, Raquel Villuendas, Miguel A. Piris

Blood (2010) 116 (21): 2468.

https://doi.org/10.1182/blood.V116.21.2468.2468

Published: 2010

Journal Articles

Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples

Beatriz Herreros, Shaomeng Wang, Maria E. Rodriguez, Margarita Sanchez-Beato, Elena Domenech, Raul Cordoba, Julio Delgado, Jose A Garcia-Marco, MD, PhD, Juan F. Garcia, José Francisco Tomás, Joaquín Martínez-López, Jose Luis Bello, Antonia Rodriguez, Raquel Villuendas, Miguel A. Piris

Blood (2010) 116 (21): 2470.

https://doi.org/10.1182/blood.V116.21.2470.2470

Published: 2010

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Francesc Bosch, MD, PhD, Neus Villamor, Pau Abrisqueta, MD, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, MD, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD

Blood (2010) 116 (21): 1382.

https://doi.org/10.1182/blood.V116.21.1382.1382

Published: 2010

Journal Articles

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Francesc Bosch, MD, PhD, Ana Muntañola, MD, Neus Villamor, MD, Maria Jose Terol, MD, Elena Gonzalez-Barca, MD, Josep Maria Ribera, MD, PhD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Felix Carbonell, MD, PhD, Jose A. Garcia-Marco, MD, PhD, Lourdes Escoda, MD, Secundino Ferrer, MD, E. Monzo, MD, Yolanda Gonzalez, MD, Pau Abrisqueta, MD, Olga Salamero, MD, Eva Gine, MD, Emili Montserrat, MD, PhD

Blood (2007) 110 (11): 626.

https://doi.org/10.1182/blood.V110.11.626.626

Published: 2007

Journal Articles

Alemtuzumab as a Single Agent or Combined with Methylprednisolone (MPD) or Fludarabine (FDR) for the Treatment of CLL Patients with p53 and ATM Deletions.

A. Sebrango, MD, A. De la Iglesia, MD, J.A. Garcia-Vela, MD, S. Ferrer, MD, E. Ruiz, MD, B. Navarro, MD, R. Fores, MD, F. Carbonell, MD, P. Sanchez-Godoy, MD, M.N. Fernandez, MD, Jose A. Garcia-Marco, MD

Blood (2007) 110 (11): 3121.

https://doi.org/10.1182/blood.V110.11.3121.3121

Published: 2007

Journal Articles

Identification of Surrogate Prognostic Markers and Genes Implicated in Immunoglobulin Gene (IgV H ) Somatic Hypermutation in Small B-Cell Lymphomas.

Lorraine Tracey, PhD, Mohit Aggarwal, MD, Patrocinio Algara, PhD, Juan F. Garcia, MD, PhD, Monica Garcia-Cosio, MD, Antonia Rodriguez, MD, PhD, Nerea Martinez, PhD, Francisca I. Camacho, MD, PhD, Giovanna Roncador, PhD, Abel Sanchez-Aguilera, B.Sc, Elena Ruiz-Ballesteros, PhD, Manuela Mollejo, MD, PhD, Jose A. Garcia-Marco, MD, PhD, Miguel A. Piris, MD, PhD

Blood (2005) 106 (11): 1004.

https://doi.org/10.1182/blood.V106.11.1004.1004

Published: 2005

Journal Articles

Unrelated Single Cord Blood Transplant Supported by Co-Infusion of a Low Number of Mobilized Peripheral Blood Highly Purified CD34+ Cells from a Third Party Donor after Low Toxicity Myeloablative Conditioning. a Strategy That Makes Cord Blood Transplant Feasible for Most Patients. (An “Allostem” Study).

Manuel N. Fernandez, MD, PhD, Carmen Regidor, MD, PhD, Rafael Cabrera, MD, PhD, Elena Magro, MD, Rafael Fores, MD, Guiomar Bautista, MD, Jorge Gayoso, MD, Elena Ruiz, MD, Belen Navaro, MD, Santiago Gil, MD, Isabel Sanjuan, MD, PhD, Jose A. Garcia-Marco, MD, PhD

Blood (2004) 104 (11): 823.

https://doi.org/10.1182/blood.V104.11.823.823

Published: 2004

NARROW

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Design of a NGS Platform for the Integrated Analysis of Genetic Mutations, Copy Number Alteration and Somatic Hypermutation of IGHV in CLL

Complement Genotype and Multiparametric Laboratory Analysis to Predict Response to Eculizumab and to Adjust Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

High Cardiac Output By Microfistulas: A New Pulmonary Hypertension Mechanism in Patients with Myelofibrosis and the Impact of the Treatment with Ruxolitinib

Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results

Paroxysmal Nocturnal Hemoglobinuria and Thrombosis Before and After Eculizumab

Paroxysmal Nocturnal Hemoglobinuria and Cancer: High Incidence Of Cancer In a Large Series Of PNH Patients In a Single Center

Paroxysmal Nocturnal Hemoglobinuria and Magnetic Resonance Imaging

Efficacy and Safety Of Temsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma: Results From The Spanish Experience

Use of Romiplostim to Facilitate Platelet Engraftment in Allogeneic Hematopoietic Transplantation

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Pharmacological Inhibition of PIM Kinases In Chronic Lymphocytic Leukemia Cases with Unfavorable Prognosis Markers

Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Alemtuzumab as a Single Agent or Combined with Methylprednisolone (MPD) or Fludarabine (FDR) for the Treatment of CLL Patients with p53 and ATM Deletions.

Identification of Surrogate Prognostic Markers and Genes Implicated in Immunoglobulin Gene (IgV H ) Somatic Hypermutation in Small B-Cell Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only